ClinicalTrials.gg
RecruitingNCT06697054SLNUpdated Nov 18, 2026

Sentinel Lymph Node (SLN) Mapping With Charcoal Carbon Dye in Early Stage Cervical Cancer

An interventional study of Sentinel node biopsy with either ICG or carbon dye injection to cervix in Cervical Cancers, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled May 2024, registered Nov 2024).
  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 18, 2026Now RecruitingFirst site in Turkey (Türkiye)+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Uterine Cervical Neoplasms with a site in Turkey — 9 open to participants now, 11 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Turkey.

Planned enrollment
35th of 37
50 · median 120
Started
2024
with 5 others
No phase
25 of 43
5 open now
Primary completion
2028-06
later than 7 of 10 live
Registered
32nd of 43
by date
Lead sponsor
2 of 43
Istanbul University

Among the 43 studies in Uterine Cervical Neoplasms with a site in Turkey, this one is the 35th largest by planned enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2024, is one of 25 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 32nd registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 43 studies in Uterine Cervical Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Uterine Cervical Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

The aim of the present study is to compare the efficacy of charcoal carbon dye (CCD) in sentinel lymph node mapping compared to indocyanine green (ICG) mapping regarding detection rates, sensitivity, specificity, negative and positive predictive values in early stage cervical cancers (IA2 - IB2).

Read the detailed description

Cervical cancer continues to be a global health problem despite the advances in prevention, screening and treatment in preinvasive stages. Although radiotherapy is the mainstay of treatment across all stages, surgery with radical and non-radical hysterectomy with pelvic lymph node evaluation is preferred in younger women with early stage cervical cancer who wants to preserve ovarian and sexual functions that may otherwise be hampered by radiotherapy. Lymph node evaluation is critical during and/or after surgery (usually before hysterectomy) and offered by global institutions since hysterectomy during surgery is abandoned in case of a metastasis in pelvic / paraaortic lymph node(s) and/or necessities primary chemoradiation or adjuvant therapy as a therapeutic modality.

During the last 10-15 years surgical sentinel lymph node (SLN) evaluation instead of complete dissection pelvic / paraaortic lymphadenectomy has gained popularity with equal success, especially in cervical tumors with less than 2-4 cm in diameter. Besides, all other advantages of sentinel lymph node evaluation is alike the advantages of other sentinel lymph node evaluation in various other cancers (vulva, breast, endometrial cancers..) with less morbidity such as less vascular injury, lymphedema, lymphocyst formation and etc. Various tracers have been used for sentinel lymph node detection in cervical cancer surgery but indocyanine green (ICG) use has surpassed other SLN mapping tracers and methods and it is the most common agent for detecting SLN in gynecologic oncology. However, it needs a fairly expensive equipment and expertise either by laparoscopy or laparotomy. In the present study, investigators are planning to use charcoal carbon dye (CCD) in addition to ICG as their usual method for SLN mapping. CCD is commonly used by general surgeons for marking of colon during preoperative colonoscopy to delineate the point of resection in surgery for colorectal resection. It is cheap and does not require special equipment and easy to learn. CCD is planned to be given just as the same as giving ICG to the cervix with 1 cc injection at each site of external os (3 and 9 o'clock position, 0.5 cc given to submucosal area and 0.5 given stroma of cervix). 20 minutes following the injection of both agents, laparoscopic dissection of retroperitoneal area will be performed to detect pelvic and paraaortic sentinel lymph nodes (up to inferior mesenteric artery) with ICG and/or CCD.

The aim of the present study is to compare the efficacy of CCD in sentinel lymph node mapping compared to ICG mapping regarding detection rates, sensitivity, specificity, negative and positive predictive values in early stage cervical cancers (IA2 - IB2).

03

Conditions studied

  • Cervical Cancers

Keywords

  • cervical cancer
  • indocyanine green
  • ICG
  • carbon dye
  • sentinel lymph node
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Early stage cervical cancer Stage IA-IB3

-

Exclusion Criteria:

1.Pervious radiotherapy 2.Age less than 18 3.Previous pelvic retroperitoneal surgery

-

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Two different tracers as a sentinel lymph node agent will be compared in early cervical cancer

    Two different tracers, one charcoal carbon dye and other indocyanine used as sentinel lymph node agent will be compared in early cervical cancer in terms of detection rates, sensitivity, specificity, negative and positive predictive value. Both tracers will be used in the patient.

    Diagnostic Test: Sentinel node biopsy with either ICG or carbon dye injection to cervix

Interventions

  • Diagnostic testSentinel node biopsy with either ICG or carbon dye injection to cervix

    Either laparatomy or laparoscopy wil be performed to detect sentinel node stained with either ICG or carbon dye injected to cervix. A hemipelvis in which a sentinel is not found will be subjected to full lymphadenectomy.

06

What researchers measure

Primary outcomes

  1. Detection rate of sentinel lymph node(s)

    Detection rate of sentinel lymph node(s) either by carbon dye or ICG unilaterally or bilaterally will be recorded and compared.

    Time frame: Two years

  2. Specifity of sentinel lymph node mapping by carbon dye or ICG

    Sensitivities of both tracers for malignancy will be compared to each other

    Time frame: Two years

  3. Sensitivity of both tracers will be compared.

    Sensitivity of both tracers will be compared for malignant metastasis

    Time frame: Two years

  4. Sensitivity of both tracers will be compared.

    Positive and negative predictive values of both tracers for malignant metastasis will be compared.

    Time frame: Two years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • ASGE Technology Committee; Kethu SR, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, Kwon RS, Mamula P, Pedrosa MC, Rodriguez SA, Wong Kee Song LM, Tierney WM. Endoscopic tattooing. Gastrointest Endosc. 2010 Oct;72(4):681-5. doi: 10.1016/j.gie.2010.06.020. PubMed 20883844 ↗
  • Sun W, Chen X, Fu S, Huang X. Feasibility of Sentinel Lymph Node Mapping With Carbon Nanoparticles in Cervical Cancer: A Retrospective Study. Cancer Control. 2023 Jan-Dec;30:10732748231195716. doi: 10.1177/10732748231195716. PubMed 37624147 ↗
  • Holloway RW, Abu-Rustum NR, Backes FJ, Boggess JF, Gotlieb WH, Jeffrey Lowery W, Rossi EC, Tanner EJ, Wolsky RJ. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 Aug;146(2):405-415. doi: 10.1016/j.ygyno.2017.05.027. Epub 2017 May 28. PubMed 28566221 ↗
  • Margioula-Siarkou C, Almperis A, Gullo G, Almperi EA, Margioula-Siarkou G, Nixarlidou E, Mponiou K, Papakotoulas P, Sardeli C, Guyon F, Dinas K, Petousis S. Sentinel Lymph Node Staging in Early-Stage Cervical Cancer: A Comprehensive Review. J Clin Med. 2023 Dec 20;13(1):27. doi: 10.3390/jcm13010027. PubMed 38202034 ↗

Individual participant data

Plan to share: Yes — All data will be shared except personal privacy related ones

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: two years

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2028, 49 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 49 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → Jun 2028 and completion Jun 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2024
First posted
Nov 20, 2024
StartActual
May 12, 2024
Primary completionEst.
Jun 2028was May 2026
CompletionEst.
Aug 2028was Jun 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 18, 2026
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · İ̇stanbul, Turkey
Nov 18, 2026
Primary completion
May 12, 2026→Jun 2028
Nov 18, 2026
Study completion
Jun 12, 2026→Aug 2028
Nov 18, 2026
Enrollment
60→50
Nov 18, 2026
Contact
Study contact now listed: added m•••@icloud.com · •••1051; added y•••@gmail.com · •••4361. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Active, not recruiting→Recruiting
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Istanbul University Med Fac Dept. of Obstet and Gynecol. Division of Gynecologic Oncology · İ̇stanbul, Turkey
    Primary completion May 12, 2026→Jun 2028
    Study completion Jun 12, 2026→Aug 2028
    Enrollment 60→50
    Contact Study contact now listed: added m•••@icloud.com · •••1051; added y•••@gmail.com · •••4361. See the current contact
    + 4 other changes: identifiers, verification date, oversight details and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06697054
Responsible party
Mustafa Albayrak (Principal Investigator, Istanbul University) — Principal investigator
First posted
Nov 20, 2024
Start date
May 12, 2024
Primary completion
Jun 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Mustafa Albayrak, MD,Gynecologic Oncology Fellow
Contact
mustafaalbayrak@icloud.com
+90 532 6871051
Yagmur Minareci, M.D.,Gynec. Oncol Specialist
Contact
yagmurminareci@gmail.com
+905053574361
Yavuz Salihoglu, Prof. Dr.
study director · ISTANBUL UNİVERSİTY MED FAC DEPT. OF OBSTET AND GYNECOL. DIVISION OF GYNECOLOGİC ONCOLOGY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion